Experimental vax could reverse Parkinson's

An experimental vaccine being studied at the University of Nebraska Medical Center successfully spurred the development of dopamine-producing nerve cells, reversing the disease in mice. And after more than a decade of work on the vaccine, the scientists are anxious to determine if the same vaccine strategy would also work in humans. Story

Suggested Articles

Gilead Sciences is paying Nurix $45 million upfront in a deal that could reach $2.3 billion in value if all milestones are met and royalties realized.

In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.

The report features testimony that some NHS bodies are “actively instructed not to deal with industry by their local leadership.”